What are the effects of Ozempic (semaglutide) on weight management and metabolic health in individuals without diabetes?
November 8, 2024
Semaglutide, marketed as Ozempic, is increasingly utilized for weight management in individuals without diabetes, demonstrating significant efficacy in clinical trials. Administration of semaglutide at 2.4 mg weekly can lead to substantial weight loss, improved anthropometric measures, and enhanced cardiometabolic health outcomes (1, 6, 14). The STEP program and other clinical trials have consistently shown that semaglutide leads to sustained weight loss and metabolic improvements in non-diabetic populations (1, 6, 39).
The mechanism by which semaglutide induces weight loss includes appetite suppression, delayed gastric emptying, and enhanced insulin sensitivity, contributing to its effects on weight and metabolic parameters (2, 25, 44). Studies reveal an average weight reduction between 10% and 15% when used in conjunction with lifestyle interventions over extended periods (3, 6, 39). Additionally, semaglutide appears to favorably impact glucose metabolism, inflammation, and cardiovascular parameters, indicating broader metabolic benefits (26, 33).
Despite its efficacy, semaglutide's use is accompanied by adverse effects, primarily gastrointestinal, though these are generally manageable and transient (1, 32). Notably, concerns exist regarding its aesthetic effects, such as "Ozempic face," and potential misuse for off-label weight loss in non-medically supervised settings (19, 44). These issues underscore the importance of using semaglutide under proper medical supervision to mitigate adverse effects and prevent inappropriate use (16, 44).
In conclusion, semaglutide offers an effective pharmacological option for weight management in individuals without diabetes, with significant evidence supporting its ability to achieve notable weight loss and improve metabolic health. Ongoing research should focus on long-term safety, especially in non-diabetic populations, and strategies to optimize its integration with lifestyle interventions for sustainable obesity management (26, 42).
References
1. Amaro, Anastassia, Danny Sugimoto, and Sean Wharton. "Efficacy and safety of semaglutide for weight management: evidence from the STEP program." Postgraduate Medicine 134.sup1 (2022): 5-17.
2. Chothave, Madhura S., Anupama A. Kapadnis, and Manoj J. Jagtap. "GLP-1 Receptor Agonists: Mechanisms, Insights, and the Impact of Wegovy and Ozempic on Contemporary Weight Management." Pharmaceutical Research: Recent Advances and Trends (2024): 91.
3. Perreault, Leigh, et al. "Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program." Diabetes Care 45.10 (2022): 2396-2405.
4. Altywaiq, Abdullah Mohammed, et al. "Ozempic and Wegovy for Weight Loss, Pharmacological Component and Effect." Journal of Namibian Studies: History Politics Culture 31 (2022): 167-180.
5. Ryan, Donna H., et al. "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial." Nature medicine (2024): 1-9.
6. Wilding, John PH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384.11 (2021): 989-1002.
7. Huang, Chengxiang. "The Role of Semaglutide in Weight Management: An Analysis of Clinical Studies for Overweight and Obese Adults." Journal of Education, Humanities and Social Sciences 27 (2024): 551-558.
8. Rubino, Domenica M., et al. "Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial." Jama 327.2 (2022): 138-150.
9. Fornes, Abby, et al. "Once-weekly semaglutide for weight management: a clinical review." Journal of Pharmacy Technology 38.4 (2022): 239-246.
10. Kurtzhals, Peter, Frederik Flindt Kreiner, and Rubdeep Singh Bindra. "The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide." Diabetes Research and Clinical Practice 203 (2023): 110881.
11. Grech, Vasiliki Sofia, et al. "Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians." (2024).
12. Levy, Matthew E., et al. "Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort study." medRxiv (2024): 2024-10.
13. Sivo-Souza, Katrina. "Diabetic Management with GLP1-RA Ozempic and Diabetic Education." (2024).
14. Gao, Xueqin, et al. "Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials." Frontiers in pharmacology 13 (2022): 935823.
15. Singh, Gurdeep, Matthew Krauthamer, and Meghan Bjalme-Evans. "Wegovy (semaglutide): a new weight loss drug for chronic weight management." Journal of Investigative Medicine 70.1 (2022): 5-13.
16. Alagan, Lakshya. "Exploring the Effects of GLP-1 Agonists on Weight Management in Non-Diabetic Individuals." Berkeley Scientific Journal 28.2 (2024).
17. Cooke, Emily. "Digesting Ozempic: How information sources on the type 2 diabetes drug Ozempic can affect patient understanding and decision making." (2023).
18. Rodriguez, Patricia J., et al. "Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity." JAMA Internal Medicine 184.9 (2024): 1056-1064.
19. Montecinos, Karen, Barbara Kania, and David J. Goldberg. "Semaglutide Ozempic Face and Implications in Cosmetic Dermatology." Dermatological Reviews 5.5 (2024): e70003.
20. Davies, Melanie, et al. "Semaglutide 2 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial." The Lancet 397.10278 (2021): 971-984.
21. Humphrey, Clinton D., and Anna C. Lawrence. "Implications of ozempic and other semaglutide medications for facial plastic surgeons." Facial Plastic Surgery 39.06 (2023): 719-721.
22. Moyad, Mark A. "Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)." Current Urology Reports 24.11 (2023): 515-525.
23. Rubino, Domenica, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial." Jama 325.14 (2021): 1414-1425.
24. Feier, Catalin Vladut Ionut, et al. "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review." International Journal of Molecular Sciences 25.8 (2024): 4346.
25. Guszczyk, Agnieszka, et al. "Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity." Quality in Sport 17 (2024): 53683-53683.
26. Verma, Subodh, et al. "Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials." EClinicalMedicine 55 (2023).
27. Mailhac, Aurlie, et al. "Semaglutide (Ozempic) Use in Denmark 2018 Through 2023 User Trends and off-Label Prescribing for Weight Loss." Clinical epidemiology (2024): 307-318.
28. Gasoyan, Hamlet, et al. "One-year weight reduction with semaglutide or liraglutide in clinical practice." JAMA Network Open 7.9 (2024): e2433326-e2433326.
29. Capehorn, M. S., et al. "Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 13 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)." Diabetes & metabolism 46.2 (2020): 100-109.
30. Ghusn, Wissam, et al. "Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity." JAMA Network Open 5.9 (2022): e2231982-e2231982.
31. Baser, Onur, et al. "Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study." Obesity Science & Practice 10.3 (2024): e762.
32. Qin, Wenhui, et al. "Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial." Diabetes, Obesity and Metabolism 26.3 (2024): 911-923.
33. Patoulias, Dimitrios, et al. "Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials." Journal of Diabetes and its Complications 37.8 (2023): 108529.
34. Handelsman, Yehuda, et al. "Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists." Journal of Managed Care & Specialty Pharmacy 24.9-a Suppl (2018): S14-S29.
35. Khawagi, Wael Y., et al. "KSA Patients with Obesity: Their Knowledge and Awareness Level of the Side Effects of Ozempic." Age 21.665 (2023): 45-9.
36. Mahapatra, Manoj Kumar, Muthukumar Karuppasamy, and Biswa Mohan Sahoo. "Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes." Reviews in Endocrine and Metabolic Disorders 23.3 (2022): 521-539.
37. Wadden, Thomas A., et al. "Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial." Jama 325.14 (2021): 1403-1413.
38. Blher, Matthias, et al. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial." Diabetologia 67.3 (2024): 470-482.
39. Zhong, Ping, et al. "Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis." Endocrine 75.3 (2022): 718-724.
40. McCrimmon, Rory J., et al. "Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial." Diabetologia 63 (2020): 473-485.
41. Prillaman, McKenzie. "Obesity drugs arent always forever. What happens when you quit?." Nature 628.8008 (2024): 488-490.
42. Tilinca, Mariana Cornelia, et al. "Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide-1 receptor agonist." Experimental and Therapeutic Medicine 22.4 (2021): 1-11.
43. Mayer, Craig S., and Paul Fontelo. "Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program." Diabetes, Obesity and Metabolism (2024).
44. Wojtara, Magda, et al. "Examining Off-Label Prescribing of Ozempic for Weight-Loss." (2023).
45. Alkhalifah, Mohammed, et al. "Semaglutide for the management of diabesity: The real-world experience." World Journal of Methodology 14.3 (2024): 91832.
46. Fonseca, Vivian A., et al. "Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide." The Journal of Clinical Endocrinology & Metabolism 104.9 (2019): 4078-4086.
47. AlGamdi, Khaled, et al. "Knowledge, Attitude, and Practice Level of Using Diabetes Medication to Lose Weight for Non-Diabetic Patients." Archives of Pharmacy Practice 13.1-2022 (2022): 55-62.
48. Enebo, Lone B., et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2 4 mg for weight management: a randomised, controlled, phase 1b trial." The Lancet 397.10286 (2021): 1736-1748.
49. Aroda, Vanita R., et al. "Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 17 trials." Diabetes & metabolism 45.5 (2019): 409-419.
50. Baser, Onur, et al. "Impact of Semaglutide on Osteoarthritis Risk in Obese Patients: A Retrospective Cohort Study." (2023).